Sintilimab FDA Approval Status

FDA Approved: No
Generic name: sintilimab
Company: Eli Lilly and Company
Treatment for: Non Small Cell Lung Cancer

Sintilimab is an investigational PD-1 inhibitor in development for the treatment of patients with nonsquamous non-small cell lung cancer (NSCLC).

Development timeline for sintilimab

Date	Article
Oct 9, 2023	First Patient Dosed in the Phase 3 Clinical Study of Efdamrofusp Alfa For the Treatment of Neovascular Age-related Macular Degeneration
Mar 24, 2022	Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer
Nov 21, 2021	Innovent Releases the ORIENT-31 Phase 3 Study First Interim Analysis Results of Sintilimab plus Byvasda® (bevacizumab biosimilar injection) and Chemotherapy in Patients with EGFR-mutated Nonsquamous Non-small Cell Lung Cancer who Progressed After EGFR-TKI
May 18, 2021	U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.